Vilin Bio Med

Why is Vilin Bio Med Ltd falling/rising?

As of 06-Aug, Vilin Bio Med Ltd's stock price is currently at 42.75, reflecting a decline of 4.89%. Despite a strong year-to-date increase of 104.06%, recent underperformance and its position below moving averages indicate ongoing price challenges.

As of 06-Aug, Vilin Bio Med Ltd's stock price is falling, currently at 42.75, which reflects a change of -2.2 or -4.89%. This decline is evident as the stock has underperformed its sector today by the same percentage. Over the past month, the stock has experienced a significant drop of 12.76%, contrasting with the Sensex, which has gained 0.84% in the same period. <BR><BR>Despite the recent downturn, the stock has shown strong performance year-to-date, with a remarkable increase of 104.06%, while the Sensex has decreased by 5.72%. Additionally, over the past year, the stock has risen by 57.75%, significantly outperforming the Sensex's modest gain of 0.25%. <BR><BR>Investor participation appears to be increasing, as indicated by a delivery volume of 24,000 shares on 05 August, which is 150% higher than the 5-day average. However, the stock's current price is lower than its 20-day and 50-day moving averages, suggesting that recent trends may be contributing to the price decline. Overall, the combination of recent underperformance and the stock's position relative to moving averages are key factors in the current falling price of Vilin Bio Med Ltd.

Which are the latest news on Vilin Bio Med?

What does Vilin Bio Med do?

Vilin Bio Med Ltd is a micro-cap pharmaceutical company focused on producing tablets, capsules, and dry syrups, with over 1000 drug approvals in various therapeutic areas since its inception in 2005. Its current market cap is INR 81 Cr, with a P/E ratio of 38.00 and a debt-equity ratio of 0.11.

Overview: <BR>Vilin Bio Med Ltd is a micro-cap company operating in the Pharmaceuticals & Biotechnology industry, focusing on the production of pharmaceutical products, including tablets, capsules, and dry syrups.<BR><BR>History: <BR>Vilin Bio Med Limited was incorporated on June 29, 2005, and commenced business on July 11, 2005. The company began its first commercial production in 2006 and expanded its facilities in 2007. By 2010, it had acquired more than 1000 drug approvals in various therapeutic areas, including diabetes, neurology, and cardiology.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: N/A <BR>Most recent Net Profit: N/A <BR>Market-cap value: INR 81 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 38.00 <BR>Industry P/E: N/A <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.11 <BR>Return on Equity: 0.95% <BR>Price-to-Book: 3.39 <BR><BR>Contact Details: <BR>Registrar Address: Not available. <BR>Phone: Not available. <BR>Email: Not available. <BR>Website: Not available.

How big is Vilin Bio Med?

As of 10th June, Vilin Bio Med Ltd has a market capitalization of 81.00 Cr, classifying it as a Micro Cap company, with no valid financial data available for net sales or net profit for the latest four quarters. Shareholder's Funds are 23.06 Cr and Total Assets are 27.73 Cr as of March 2025.

As of 10th June, <BR><BR>Market Cap: Vilin Bio Med Ltd has a market capitalization of 81.00 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: There is no valid financial data available for net sales or net profit for the latest four quarters.<BR><BR>Balance Sheet Snapshot: The reporting period is March 2025, with Shareholder's Funds amounting to 23.06 Cr and Total Assets valued at 27.73 Cr.

Who are the peers of the Vilin Bio Med?

Vilin Bio Med's peers include Onyx Biotec, Zenith Drugs, Ajooni Biotech, and others. Vilin Bio Med has a below-average management risk and a 1-year return of 75.50%, outperforming its peers, with Vineet Laborator leading at 58.84%.

Peers: The peers of Vilin Bio Med are Onyx Biotec, Zenith Drugs, Ajooni Biotech, Vineet Laborator, Bacil Pharma, Bharat Immunolog, Phaarmasia, Source Natural, and Amwill Health.<BR><BR>Quality Snapshot: Excellent management risk is observed at Source Natural and Amwill Health, while Average management risk is found at Onyx Biotec. Below Average management risk is noted at Vilin Bio Med, Zenith Drugs, Ajooni Biotech, Vineet Laborator, Bharat Immunolog, Phaarmasia, and the rest. Good capital structure is seen at Ajooni Biotech, while Below Average capital structure is present at Vilin Bio Med, Onyx Biotec, Zenith Drugs, Vineet Laborator, Bharat Immunolog, Phaarmasia, and the rest. Bacil Pharma does not qualify in any category.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Vineet Laborator at 58.84%, while Onyx Biotec has the lowest at -20.00%. Vilin Bio Med's 1-year return of 75.50% is significantly higher than both. Additionally, Ajooni Biotech, Zenith Drugs, and Bacil Pharma have negative six-month returns.

How has been the historical performance of Vilin Bio Med?

Vilin Bio Med's historical performance shows fluctuating sales growth, peaking at INR 15.80 crore in March 2024, but facing rising raw material costs and declining profits, with net profit after tax dropping to INR 0.22 crore by March 2025. Despite a decrease in total liabilities, the company has struggled with negative cash flow from operations.

Answer:<BR>The historical performance of Vilin Bio Med shows a fluctuating trend in key financial metrics over the past five years.<BR><BR>Breakdown:<BR>Vilin Bio Med's net sales have shown a general increase from INR 11.21 crore in March 2022 to INR 15.80 crore in March 2024, before slightly declining to INR 14.81 crore in March 2025. The total operating income followed a similar trend, peaking in March 2024. However, the raw material costs have risen significantly, from INR 9.06 crore in March 2021 to INR 13.47 crore in March 2025, impacting the operating profit, which decreased from INR 2.59 crore in March 2023 to INR 1.25 crore in March 2025. Profit before tax also declined from INR 1.78 crore in March 2023 to INR 0.31 crore in March 2025, while profit after tax dropped from INR 1.25 crore in March 2023 to INR 0.22 crore in March 2025. The company's total liabilities decreased from INR 32.40 crore in March 2024 to INR 27.73 crore in March 2025, with a notable reduction in short-term borrowings. Cash flow from operating activities has remained negative, with a net cash outflow of INR 5 crore in March 2025. Overall, while Vilin Bio Med has seen growth in sales and income, rising costs and declining profits indicate challenges in maintaining profitability.

Is Vilin Bio Med overvalued or undervalued?

As of September 23, 2025, Vilin Bio Med is considered very expensive with a PE ratio of 35.50, significantly higher than peers like Sun Pharma and Cipla, despite outperforming the Sensex with a 41.27% return over the past year.

As of 23 September 2025, the valuation grade for Vilin Bio Med has moved from expensive to very expensive, indicating a significant increase in perceived overvaluation. The company is currently assessed as overvalued, with a PE ratio of 35.50, an EV to EBIT of 38.02, and a PEG ratio of 0.95. These metrics suggest that the stock is trading at a premium compared to its earnings growth potential.<BR><BR>In comparison to its peers, Vilin Bio Med's PE ratio is higher than Sun Pharma's 34.11 and significantly above Cipla's more attractive 22.93. Additionally, while Divi's Lab shows a very expensive valuation with a PE of 69.64, it highlights the disparity within the sector. Notably, Vilin Bio Med has outperformed the Sensex over the past year with a return of 41.27%, contrasting with the Sensex's decline of 2.97%. This performance, however, does not mitigate the concerns regarding its current valuation levels.

Who are the top shareholders of the Vilin Bio Med?

The top shareholders of Vilin Bio Med are Venkata Bhagi Rao Sadhanala with 32.79%, followed by public shareholder Percy Homi Italia at 4.29%, and individual investors holding a total of 34.18%. There are no holdings by mutual funds or foreign institutional investors.

The top shareholders of Vilin Bio Med include the promoters, with Venkata Bhagi Rao Sadhanala holding the largest share at 32.79%. The highest public shareholder is Percy Homi Italia, who owns 4.29%. Additionally, individual investors collectively hold 34.18% of the company's shares. There are currently no holdings by mutual funds or foreign institutional investors (FIIs).

What is the technical trend for Vilin Bio Med?

As of June 3, 2025, Vilin Bio Med's technical trend is mildly bullish, supported by a bullish weekly MACD and Bollinger Bands, despite bearish signals from the RSI and Dow Theory.

As of 3 June 2025, the technical trend for Vilin Bio Med has changed from bullish to mildly bullish. The weekly MACD remains bullish, while the RSI is bearish, indicating some weakness in momentum. The Bollinger Bands are bullish on both weekly and monthly time frames, supporting the mildly bullish stance. Daily moving averages are also bullish, suggesting short-term strength. However, Dow Theory indicates bearish trends on both weekly and monthly levels, which could be a concern. The On-Balance Volume (OBV) shows a mildly bullish signal weekly but is mildly bearish monthly, adding to the mixed signals. Overall, the current technical stance is mildly bullish, driven primarily by the weekly MACD and Bollinger Bands, despite bearish signals from the RSI and Dow Theory.

When is the next results date for Vilin Bio Med?

No Upcoming Board Meetings

Has Vilin Bio Med declared dividend?

No Dividend History Available